A Randomized Investigator And Subject-Blind, Sponsor Open, Placebo Controlled Phase 1 Study To Characterize The Safety, Tolerability, And Pharmacokinetics Of Ascending Multiple Doses Of PF-05212377 (SAM-760) Administered Orally To Healthy Young And Elderly Subjects.

Trial Profile

A Randomized Investigator And Subject-Blind, Sponsor Open, Placebo Controlled Phase 1 Study To Characterize The Safety, Tolerability, And Pharmacokinetics Of Ascending Multiple Doses Of PF-05212377 (SAM-760) Administered Orally To Healthy Young And Elderly Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2011

At a glance

  • Drugs PF 5212377 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Feb 2011 Actual patient number is 60 as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Aug 2010 Additional trial location [France] identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top